<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00199563</url>
  </required_header>
  <id_info>
    <org_study_id>R-04-402</org_study_id>
    <secondary_id>Ethics Review: 10331</secondary_id>
    <secondary_id>R-04-402</secondary_id>
    <nct_id>NCT00199563</nct_id>
  </id_info>
  <brief_title>Use of Sildenafil (Viagra) in Diabetic Men With Erectile Dysfunction: the Impact on Blood Vessels</brief_title>
  <official_title>The Use and Efficacy of Sildenafil in Diabetic Men With Erectile Dysfunction: the Impact on Endothelial Function, a Pilot Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lawson Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lawson Health Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  To evaluate the impact of nightly sildenafil vs placebo use on diabetic men with and
           without proven endothelial dysfunction and coexisting erectile concerns.

        -  To determine if chronic sildenafil use compared to placebo positively impacts
           endothelial function among a cohort of diabetic mend with erectile dysfunction

        -  To assess the salvage rate of sildenafil - failures who demonstrate improved response
           rates over time with chronic use

        -  To assess if microalbuminuria predicts flow-mediated dilation (FMD) response

        -  To measure and identify if other patient specific characteristics predict for sildenafil
           erectile response and flow-mediated dilatation (FMD) response over time (patient
           specifics; blood pressure, HBA1c, weight, BMI, age IIEF score at baseline)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      60 type II diabetic men with erectile dysfunction will be enrolled in this trial, evaluated
      over a 12 week period. Randomization into one of two arms (placebo, daily sildenafil 50mg)
      will be a doubly blinded. Subjects will be followed by IIEF, diaries and brachial forearm
      medial dilatation duplex scans, urinary microalbuminuria and serum chemistry.

      Study time-points are at baseline, 6 and 12 weeks.

      Study participants will be instructed to use the study medication at the specified frequency
      but will be allowed flexibility to suit their erectile needs.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine if PDE5 use over 12 week period in ED diabetic men improves endothelial function as measured by FMD of the brachial artery, as compared to placebo; Assess treatment response to sildenafil over a 12 week period of exposure compared to placebo.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>IIEF Questionnaire &amp; diary response;Blood pressure and microalbuminuria; Side effects</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Impotence</condition>
  <arm_group>
    <arm_group_label>active drug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Viagra 100 mg / daily for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo/daily for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Viagra</intervention_name>
    <description>Sildenafil 100mg daily for 12 weeks</description>
    <arm_group_label>active drug</arm_group_label>
    <other_name>Sildenafil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years of age

          -  Type 2 diabetes &gt; 6 months in duration. Men using oral hypoglycemic agents and /or
             insulin will be permitted into the trial.

          -  Stable hetero- sexual relationship for &gt; 6 months

          -  IIEF score at baseline &lt;21Â·

          -  Agrees to sign informed consent

        Exclusion Criteria:

          -  Known hypersensitivity to sildenafil

          -  Use of nitrates

          -  Use of anti-coagulants

          -  History of significant heart disease, +/or myocardial infarction within last 6 months

          -  Unable to understand or unwilling to sign informed consent

          -  Concomitant use of erectogenic agent during study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerald B Brock, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lawson Health Research Institute/St. Joseph's Health Care London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Joseph's Health Care London/Urology Clinic</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4V2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <results_reference>
    <citation>Yu HI, Sheu WH, Lai CJ, Lee WJ, Chen YT. Endothelial dysfunction in type 2 diabetes mellitus subjects with peripheral artery disease. Int J Cardiol. 2001 Mar;78(1):19-25.</citation>
    <PMID>11259809</PMID>
  </results_reference>
  <results_reference>
    <citation>De Angelis L, Marfella MA, Siniscalchi M, Marino L, Nappo F, Giugliano F, De Lucia D, Giugliano D. Erectile and endothelial dysfunction in Type II diabetes: a possible link. Diabetologia. 2001 Sep;44(9):1155-60.</citation>
    <PMID>11596671</PMID>
  </results_reference>
  <results_reference>
    <citation>Feldt-Rasmussen B. Microalbuminuria, endothelial dysfunction and cardiovascular risk. Diabetes Metab. 2000 Jul;26 Suppl 4:64-6. Review.</citation>
    <PMID>10922975</PMID>
  </results_reference>
  <results_reference>
    <citation>Desouza C, Parulkar A, Lumpkin D, Akers D, Fonseca VA. Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes. Diabetes Care. 2002 Aug;25(8):1336-9.</citation>
    <PMID>12145231</PMID>
  </results_reference>
  <results_reference>
    <citation>Dishy V, Sofowora G, Harris PA, Kandcer M, Zhan F, Wood AJ, Stein CM. The effect of sildenafil on nitric oxide-mediated vasodilation in healthy men. Clin Pharmacol Ther. 2001 Sep;70(3):270-9.</citation>
    <PMID>11557915</PMID>
  </results_reference>
  <results_reference>
    <citation>Katz SD, Balidemaj K, Homma S, Wu H, Wang J, Maybaum S. Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol. 2000 Sep;36(3):845-51.</citation>
    <PMID>10987609</PMID>
  </results_reference>
  <verification_date>September 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>January 24, 2013</last_update_submitted>
  <last_update_submitted_qc>January 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lawson Health Research Institute</investigator_affiliation>
    <investigator_full_name>Gerald Brock</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Viagra</keyword>
  <keyword>sildenafil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

